A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT01268059

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01268059. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer (NSCLC).

Study identification

NCT ID: NCT01268059
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: MedImmune LLC; Industry
Enrollment: 99 participants

Conditions and interventions

Conditions

Non-small Cell Lung Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 99 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 16, 2010 (Actual)
Primary completion: Sep 11, 2013 (Actual)
Completion: Sep 11, 2013 (Actual)
Last update posted: Dec 23, 2020

2010 – 2013

United States locations

U.S. sites: 19
U.S. states: 14
U.S. cities: 18

Facility	City	State	ZIP	Site status
Research Site	Fountain Valley	California	92708	—
Research Site	Oxnard	California	93030	—
Research Site	Chicago	Illinois	60637	—
Research Site	Lafayette	Indiana	47905	—
Research Site	Baton Rouge	Louisiana	70809	—
Research Site	Annapolis	Maryland	21401	—
Research Site	Baltimore	Maryland	21204	—
Research Site	Baltimore	Maryland	21231	—
Research Site	Boston	Massachusetts	02114	—
Research Site	Danvers	Massachusetts	01923	—
Research Site	Detroit	Michigan	48201	—
Research Site	Omaha	Nebraska	68144	—
Research Site	Lake Success	New York	11042	—
Research Site	Canton	Ohio	44718	—
Research Site	Hershey	Pennsylvania	17033-0850	—
Research Site	Hilton Head Island	South Carolina	29926	—
Research Site	Chattanooga	Tennessee	37404	—
Research Site	Corpus Christi	Texas	78404	—
Research Site	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01268059, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 23, 2020 · Synced Nov 12, 2026